ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1013

Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis

Olivier Fogel1, Maud Fagny 2, Elodie Roche 3, Nelly Sigrist 3, Jean-François Deleuze 4, Maxime Dougados 5, Corinne Miceli-Richard 1 and Jorg Tost 3, 1Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, 2CEA-CNRGH-Institut François Jacob- Laboratoire Epigenetique et Envrironnement, Evry, Ile-de-France, France, 3CEA-CNRGH-Institut François Jacob- Laboratoire Epigenetique et Envrironnement, Evry, France, 4CEA-CNRGH-Institut François Jacob, Evry, France, 5Cochin Hospital, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, Epigenetics, MicroRNA and anti-TNF therapy, mir

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: TNFα inhibitors are an effective treatment for many inflammatory diseases. However, their mechanism of action is more complicated than just blocking the targeted cytokine. MicroRNAs are important post-translational regulators of gene expression and their expression has been found deregulated in rheumatic diseases such as rheumatoid arthritis or spondyloarthritis. The general goal of this work is to investigate changes in miR expression in monocytes and CD4+ T-lymphocytes from patients with axial spondyloarthritis during anti-TNF treatment.

Methods: Sixty-eight patients with axial spondyloarthritis were enrolled in the study. Among these patients, 63 fulfilled the 2009 ASAS classification criteria (imaging arm) with sacro-iliitis on X-rays (n= 47) or objective signs of inflammation on MRI (n=16) and 72% were HLA-B27 positive.  All patients were naïve for biologic treatments at baseline and had an active disease (mean BASDAI score of 49 +/- 19 and mean ASDAS score of 3+/-1) requiring the initiation of a TNFα inhibitor (Etanercept 41, Adalimumab 17, Golimumab 10). Mean CRP at baseline was 12.5 +/-18. At 3 months, the BASDAI response rate was 59%.  Blood sample were collected at baseline (M0) and 3 months (M3) after the initiation of the treatment. Monocytes and CD4+ T-lymphocytes were isolated from peripheral blood mononuclear cells and 372 miR were investigated by qPCR. A paired Wilcoxon signed-rank test was used to explore differential expression of miRs between M0 and M3.

Results: Pair-wise comparison of miR level before and 3 months after anti-TNF treatment identified 35 differentially expressed (DE) miRs in circulating CD4+ T lymphocytes and 53 DE miRs in monocytes (false discovery rate < 5%). Eighteen miRs were commonly deregulated in both cell types, among which 12 were upregulated and 6 were downregulated after treatment. Strikingly, we found DE miRs before and after treatment in patients with good response to TNF inhibitors while there was little or no DE miRs in non-responders according to BASDAI response criteria. Differentially expressed miRs were not correlated to the CRP levels or to the variation of the CRP between 0 and 3 months. Also, in patients with negative CRP at baseline, we found DE miRs (nominal p-value < 5%) suggesting that the modulation of miRs was not only reflecting a better inflammation control.

Conclusion: This work demonstrates that TNF inhibitors might at least partially act by modulating miR expression, especially in patients who respond well to treatment.


Disclosure: O. Fogel, None; M. Fagny, None; E. Roche, None; N. Sigrist, None; J. Deleuze, None; M. Dougados, AbbVie, 2, 5, 8, Amgen, 5, Biogen, 5, BMS, 2, 5, 8, Eli Lilly, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, Merck, 2, 5, Merck Inc, 2, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Pfizer Inc, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; C. Miceli-Richard, Abbott, Bristol-Myers Squibb, Merck, Pfizer, Roche, Schering-Plough, and Wyeth, 8, Abbvie, 2, 5, AbbVie, Bristol-Myers Squibb, Novartis, Merck, Pfizer, and Wyeth, 2, Biogen, 2, BMS, 5, MSD, 2, Novartis, 2, 5, Pfizer, 2, Pfizer, Roche, UCB, Wyeth, and Merck, 5, UCB, 2; J. Tost, None.

To cite this abstract in AMA style:

Fogel O, Fagny M, Roche E, Sigrist N, Deleuze J, Dougados M, Miceli-Richard C, Tost J. Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-Lymphocytes in Spondyloarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effects-of-anti-tnf-on-mir-expression-in-monocytes-and-cd4-t-lymphocytes-in-spondyloarthritis/. Accessed January 25, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effects-of-anti-tnf-on-mir-expression-in-monocytes-and-cd4-t-lymphocytes-in-spondyloarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.